
Soligenix's HyBryte Therapy Addresses Critical Gaps in Early-Stage CTCL Treatment
Soligenix is developing HyBryte, a visible light-activated photodynamic therapy that shows statistically significant efficacy in treating early-stage cutaneous T-cell lymphoma while minimizing damage to healthy tissue, addressing a challenging diagnostic and treatment landscape.
Read full story






















